Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Platinum+ Gemcitabine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cetuximab + platinum + gemcitabine | DRUG | Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance. |
| Platinum + Gemcitabine | DRUG | Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks. |
Inclusion Criteria: * Must have advanced or metastatic non-small cell lung cancer that has not been previously treated with any chemotherapy. * Must not have received cetuximab or any medications that target the same pathway as cetuximab (such as Iressa or Tarceva). * Must not have had hypersensiti...
Platinum+ Gemcitabine is a combination chemotherapy regimen being studied for the first-line treatment of patients with advanced or metastatic Non-Small-Cell Lung Carcinoma. It is an investigational small molecule therapy in Phase 2 clinical development, evaluated in a completed clinical trial.
Platinum+ Gemcitabine is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company sponsored the clinical trial evaluating this combination regimen for Non-Small-Cell Lung Carcinoma.
Platinum+ Gemcitabine is in Phase 2 clinical development. It is an investigational combination therapy, not yet approved by regulatory authorities. The Phase 2 trial for Non-Small-Cell Lung Carcinoma has been completed, and the drug remains under clinical investigation.
Platinum+ Gemcitabine was evaluated in a single completed Phase 2 clinical trial with the identifier NCT00112346. The study, titled "Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer," enrolled 120 participants in the United States and Canada.
Yes, Platinum+ Gemcitabine is the same as the Gemcitabine/Platinum combination regimen. The clinical trial NCT00112346 refers to the treatment as Gemcitabine/Platinum, and the drug is also known by the name Platinum+ Gemcitabine in the context of this study.
The Phase 2 trial NCT00112346 was a randomized, active-controlled study comparing Gemcitabine/Platinum with or without Cetuximab as first-line treatment for advanced or metastatic Non-Small-Cell Lung Cancer. It enrolled 120 adults aged 18 years and older in the United States and Canada, and the trial has been completed.